NCT01585688View on ClinicalTrials.gov

Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

November 30, 2016

Study Completion Date

October 31, 2017

Conditions
Non-Hodgkin's LymphomaChronic Lymphocytic Leukemia
Interventions
DRUG

hLL1-DOX (IMMU-115)

hLL1-DOX is administered intravenously at one of 4 dose levels on days 1, 4, 8 and 11 of 21-day treatment cycles, with up to 8 cycles administered.

Trial Locations (6)

19713

Helen F. Graham Cancer Center, Newark

32806

MD Anderson Cancer Center Orlando, Orlando

46526

IU Health Goshen Center for Cancer Care, Goshen

77030

U.T. MD Anderson Cancer Center Houston, Houston

01605

UMass Memorial Cancer Center of Excellence, Worcester

07601

John Theurer Cancer Center Hackensack University Medical Center, Hackensack

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY